Group 1 - The core viewpoint is that the policies related to the Hainan Free Trade Zone will positively impact the local business of the company, facilitating market expansion and diversification [1] - The company plans to closely monitor market dynamics in the Hainan region [1] - The company aims to actively launch tourism service products that feature local characteristics in response to market demand [1]

Core Viewpoint - Jinshi Yao (300434) has shown a positive market performance with a closing price of 10.98 yuan, reflecting a 4.87% increase as of October 31, 2025, indicating investor confidence and potential growth opportunities in the company [1]. Group 1: Company Operations - Jinshi Yao has established two subsidiaries in Hainan Province: Hainan Asia Pharmaceutical Co., Ltd. and Hainan Kuaike Pharmaceutical Co., Ltd. [2][3] - The company is actively monitoring the policies of the Hainan Free Trade Zone, which includes industry support, tariff reductions, tax incentives, and talent introduction, to leverage potential business opportunities and explore new growth points [2]. Group 2: Market Activity - On October 31, 2025, the net inflow of main funds into Jinshi Yao was 36.17 million yuan, indicating strong interest from major investors [3]. - Retail investors showed a net outflow of 38.54 million yuan, suggesting a divergence in investment sentiment between institutional and retail investors [3].